These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35394898)
21. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424 [TBL] [Abstract][Full Text] [Related]
22. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis. Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751 [TBL] [Abstract][Full Text] [Related]
24. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R; Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429 [TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Ong-Lim AL; Shukarev G; Trinidad-Aseron M; Caparas-Yu D; Greijer A; Duchene M; Scheper G; van Paassen V; Le Gars M; Cahill CP; Schuitemaker H; Douoguih M; Jacquet JM Hum Vaccin Immunother; 2022 Nov; 18(5):2044255. PubMed ID: 35344464 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months. Sáez-Llorens X; Thierry-Carstensen B; Stoey LS; Sørensen C; Wachmann H; Bandyopadhyay AS; Nielsen PI; Kusk MV Vaccine; 2020 May; 38(21):3780-3789. PubMed ID: 32273184 [TBL] [Abstract][Full Text] [Related]
27. [Immunogenicity and safety of a booster dose of inactivated polio vaccine]. Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129 [TBL] [Abstract][Full Text] [Related]
28. Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains. Tang R; Chu K; Hu Y; Chen L; Zhang M; Liu S; Ma H; Wang J; Zhu F; Hu Y; Gao Q Hum Vaccin Immunother; 2019; 15(5):1160-1166. PubMed ID: 30676838 [TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976 [TBL] [Abstract][Full Text] [Related]
30. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine. Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691 [TBL] [Abstract][Full Text] [Related]
31. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV). Okada K; Miyazaki C; Kino Y; Ozaki T; Hirose M; Ueda K J Infect Dis; 2013 Jul; 208(2):275-83. PubMed ID: 23568174 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534 [TBL] [Abstract][Full Text] [Related]
33. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278 [TBL] [Abstract][Full Text] [Related]
35. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. Satoh H; Tanaka-Taya K; Shimizu H; Goto A; Tanaka S; Nakano T; Hotta C; Okazaki T; Itamochi M; Ito M; Okamoto-Nakagawa R; Yamashita Y; Arai S; Okuno H; Morino S; Oishi K Vaccine; 2019 Mar; 37(14):1964-1971. PubMed ID: 30827736 [TBL] [Abstract][Full Text] [Related]
36. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba. Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China. Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216 [TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Snider CJ; Zaman K; Estivariz CF; Yunus M; Weldon WC; Wannemuehler KA; Oberste MS; Pallansch MA; Wassilak SG; Bari TIA; Anand A Lancet; 2019 Jun; 393(10191):2624-2634. PubMed ID: 31104832 [TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults. Leroux-Roels I; Leroux-Roels G; Shukarev G; Schuitemaker H; Cahill C; de Rooij R; Struijs M; van Zeeburg H; Jacquet JM Hum Vaccin Immunother; 2021 May; 17(5):1366-1373. PubMed ID: 33175637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]